Symptom management in gynecologic malignancies

Expert Review of Anticancer Therapy

Volumn 11, Issue 7, 2011, Pages 1079-1091

  Casey, Carolyn ^a   Chen, Lee May ^a   Rabow, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

comprehensive cancer care; gynecologic cancer; palliative care; symptom management

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BENZODIAZEPINE; CANNABIS; DESIPRAMINE; DEXAMETHASONE; DIURETIC AGENT; DOCUSATE SODIUM; DULOXETINE; FENTANYL; GABAPENTIN; HALOPERIDOL; HERBACEOUS AGENT; HYDROMORPHONE; METHADONE; METHYLPHENIDATE; METOCLOPRAMIDE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE AGONIST; OXYCODONE; PARACETAMOL; PLACEBO; PREGABALIN; PROCHLORPERAZINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACUPUNCTURE; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; ASCITES; BEDTIME DOSAGE; CANCER FATIGUE; CANCER PAIN; CONFUSION; CONSTIPATION; DELIRIUM; DEPRESSION; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DYSPHORIA; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC CANCER; HEADACHE; HEART DISEASE; HUMAN; HYPERALGESIA; INCREASED APPETITE; INSOMNIA; KINESIOTHERAPY; LOW DRUG DOSE; LYMPHEDEMA; MASSAGE; MORNING DOSAGE; MOXIBUSTION; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARACENTESIS; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRURITUS; PSYCHOTHERAPY; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SENNA; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; SYMPTOM; THERAPY EFFECT; UNPLEASANT DREAM; UNSPECIFIED SIDE EFFECT; URINE RETENTION; URTICARIA; WEIGHT GAIN; XEROSTOMIA;

EID: 79961066561     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.83     Document Type: Review

References (116)

1. von Gruenigen VE, Huang HQ, Gil KM et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 115(20), 4857-4864 (2009).
2. Portenoy RK, Kornblith AB, Wong G et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 74(3), 907-915 (1994). (Pubitemid 24237472)
3. Liu S, Ercolano E, Siefert ML, McCorkle R. Patterns of symptoms in women after gynecologic surgery. Oncol. Nurs. Forum 37(2), E133-E140 (2010).
4. Steele R, Fitch MI. Supportive care needs of women with gynecologic cancer. Cancer Nurs. 31(4), 284-291 (2008).
5. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer 98(5), 1061-1071 (2003). (Pubitemid 37022109)
6. Sun CC, Bodurka DC, Weaver CB et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4), 219-227 (2005). (Pubitemid 40576508)
7. von Gruenigen VE, Hutchins JR, Reidy AM et al. Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy. Health Qual. Life Outcomes 4, 84 (2006).
8. Fieler VK. Side effects and quality of life in patients receiving high-dose rate brachytherapy. Oncol. Nurs. Forum 24(3), 545-553 (1997).
9. Wenzel LB, Donnelly JP, Fowler JM et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 11(2), 142-153 (2002). (Pubitemid 34256425)
10. Onsrud M, Hagen B, Heimstad R. [Palliative treatment in gynecologic cancer]. Tidsskr Nor Laegeforen 121(16), 1896-1901 (2001).
11. Houck K, Avis NE, Gallant JM, Fuller AF Jr, Goodman A. Quality of life in advanced ovarian cancer: identifying specific concerns. J. Palliat. Med. 2(4), 397-402 (1999).
12. Hodgkinson K, Butow P, Fuchs A et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol. Oncol. 104(2), 381-389 (2007). (Pubitemid 46135660)
13. Beesley V, Eakin E, Steginga S, Aitken J, Dunn J, Battistutta D. Unmet needs of gynaecological cancer survivors: implications for developing community support services. Psychooncology 17(4), 392-400 (2008). (Pubitemid 351513688)
14. Klee M, Thranov I, Machin D. Life after radiotherapy: the psychological and social effects experienced by women treated for advanced stages of cervical cancer. Gynecol. Oncol. 76(1), 5-13 (2000). (Pubitemid 30048312)
15. Miller BE, Pittman B, Strong C. Gynecologic cancer patients' psychosocial needs and their views on the physician's role in meeting those needs. Int. J. Gynecol. Cancer 13(2), 111-119 (2003). (Pubitemid 37055463)
16. Wenzel L, DeAlba I, Habbal R et al. Quality of life in long-term cervical cancer survivors. Gynecol. Oncol. 97(2), 310-317 (2005). (Pubitemid 40614869)
17. Capelli G, De Vincenzo RI, Addamo A, Bartolozzi F, Braggio N, Scambia G. Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings? Cancer 95(12), 2500-2507 (2002). (Pubitemid 35424035)
18. Chan YM, Ngan HY, Li BY et al. A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol. Oncol. 83(1), 10-19 (2001). (Pubitemid 32959873)
19. Approaching death: improving care at the end of life - a report of the Institute of Medicine. Health Serv. Res. 33(1), 1-3 (1998).
20. Ferris FD, Bruera E, Cherny N et al. Palliative cancer care a decade later: accomplishments, the need, next steps - from the American Society of Clinical Oncology. J. Clin. Oncol. 27(18), 3052-3058 (2009).
21. Meier DE. Palliative care in hospitals. J. Hosp. Med. 1(1), 21-28 (2006).
22. Hilden JM, Emanuel EJ, Fairclough DL et al. Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J. Clin. Oncol. 19(1), 205-212 (2001). (Pubitemid 32063498)
23. Ramondetta LM, Tortolero-Luna G, Bodurka DC et al. Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int. J. Gynecol. Cancer 14(4), 580-588 (2004). (Pubitemid 39062911)
24. Emanuel LLFF, von Gunten CF, Von Roenn J. EPEC-O: education in palliative and end-of-life care - oncology. In: The EPEC Project. Chicago, IL, USA (2005).
25. Kirkova J, Davis MP, Walsh D et al. Cancer symptom assessment instruments: a systematic review. J. Clin. Oncol. 24(9), 1459-1473 (2006). (Pubitemid 46622014)
26. Portenoy RK, Thaler HT, Kornblith AB et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur. J. Cancer 30A(9), 1326-1336 (1994). (Pubitemid 24322071)
27. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer 62(6), 1034-1038 (1990).
28. Sitzia J, Dikken C, Hughes J. Psychometric evaluation of a questionnaire to document side-effects of chemotherapy. J. Adv. Nurs. 25(5), 999-1007 (1997). (Pubitemid 127453242)
29. Youngblood M, Williams PD, Eyles H, Waring J, Runyon S. A comparison of two methods of assessing cancer therapy-related symptoms. Cancer Nurs. 17(1), 37-44 (1994). (Pubitemid 24080587)
30. Munro AJ, Potter S. A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. Br. J. Cancer 74(4), 640-647 (1996). (Pubitemid 26279063)
31. Cleeland CS, Mendoza TR, Wang XS et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7), 1634-1646 (2000).
32. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J. Palliat. Care 7(2), 6-9 (1991).
33. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1(5), 373-378 (1978).
34. Ewing G, Todd C, Rogers M, Barclay S, McCabe J, Martin A. Validation of a symptom measure suitable for use among palliative care patients in the community: CAMPAS-R. J. Pain Symptom Manag. 27(4), 287-299 (2004). (Pubitemid 38410896)
35. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS).Cancer Invest. 22(4), 526-536 (2004). (Pubitemid 39506873)
36. Agarwal S, Bodurka DC. Symptom research in gynecologic oncology: a review of available measurement tools. Gynecol. Oncol. 119(2), 384-389 (2010).
37. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J. Clin. Oncol. 19(6), 1809-1817 (2001). (Pubitemid 32230884)
38. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11(3), 570-579 (1993). (Pubitemid 23071057)
39. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer 107(8), 1812-1822 (2006). (Pubitemid 44582950)
40. Ditto A, Martinelli F, Borreani C et al. Quality of life and sexual, bladder, and intestinal dysfunctions after class III nerve-sparing and class II radical hysterectomies: a questionnaire-based study. Int. J. Gynecol. Cancer 19(5), 953-957 (2009).
41. Janda M, Obermair A, Cella D et al. The functional assessment of cancer-vulvar: reliability and validity. Gynecol. Oncol. 97(2), 568-575 (2005). (Pubitemid 40614905)
42. Emanuel EJ, Emanuel LL. The promise of a good death. Lancet 351(Suppl. 2), SII21-SII29 (1998).
43. Suzuki T, Morishita M, Ito E, Matsuura M, Tanaka R, Saito T. Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer. Am. J. Ther. 15(1), 31-35 (2008). (Pubitemid 351161179)
44. Ward S, Donovan HS, Owen B, Grosen E, Serlin R. An individualized intervention to overcome patient-related barriers to pain management in women with gynecologic cancers. Res. Nurs. Health 23(5), 393-405 (2000).
45. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet 357(9265), 1311-1315 (2001). (Pubitemid 32441527)
46. Portenoy RK, Thaler HT, Kornblith AB et al. Symptom prevalence, characteristics and distress in a cancer population. Qual. Life Res. 3(3), 183-189 (1994). (Pubitemid 24253426)
47. Reddy S, Hui D, El Osta B et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J. Palliat. Med. 13(1), 33-38 (2010).
48. Portenoy RK, Sibirceva U, Smout R et al. Opioid use and survival at the end of life: a survey of a hospice population. J. Pain Symptom Manage. 32(6), 532-540 (2006). (Pubitemid 44872928)
49. Bengoechea I, Gutierrez SG, Vrotsou K, Onaindia MJ, Lopez JM. Opioid use at the end of life and survival in a Hospital at Home unit. J. Palliat. Med. 13(9), 1079-1083 (2010).
50. Plews-Ogan M, Owens JE, Goodman M, Wolfe P, Schorling J. A pilot study evaluating mindfulness-based stress reduction and massage for the management of chronic pain. J. Gen. Intern. Med. 20(12), 1136-1138 (2005). (Pubitemid 43115148)
51. Kutner JS, Smith MC, Corbin L et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann. Intern. Med. 149(6), 369-379 (2008).
52. Alimi D, Rubino C, Pichard-Leandri E, Fermand-Brule S, Dubreuil-Lemaire ML, Hill C. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J. Clin. Oncol. 21(22), 4120-4126 (2003). (Pubitemid 46606179)
53. Searle RD, Bennett MI, Johnson MI, Callin S, Radford H. Letter to editor: transcutaneous electrical nerve stimulation (TENS) for cancer bone pain. Palliat. Med. 22(7), 878-879 (2008).
54. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7), 515-521 (2007).
55. Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs. 17(5), 367-378 (1994). (Pubitemid 24300143)
56. Greenberg DB, Sawicka J, Eisenthal S, Ross D. Fatigue syndrome due to localized radiation. J. Pain Symptom Manage. 7(1), 38-45 (1992).
57. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin. Hematol. 34(3 Suppl. 2), 4-12 (1997). (Pubitemid 27319139)
58. Holzner B, Kemmler G, Meraner V et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97(6), 1564-1572 (2003). (Pubitemid 36297787)
59. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4(1), 1-10 (1999). (Pubitemid 29102450)
60. Sugawara Y, Akechi T, Shima Y et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat. Med. 16(3), 261-263 (2002). (Pubitemid 34537672)
61. Bruera E, Driver L, Barnes EA et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J. Clin. Oncol. 21(23), 4439-4443 (2003). (Pubitemid 46621822)
62. Bruera E, Valero V, Driver L et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 24(13), 2073-2078 (2006). (Pubitemid 46622117)
63. Johnson RL, Block I, Gold MA, Markwell S, Zupancic M. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology 19(9), 955-958 (2009).
64. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. 69(7-8), 751-754 (1985). (Pubitemid 15229409)
65. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7(5), 590-597 (1989). (Pubitemid 19126794)
66. Barton DL, Soori GS, Bauer BA et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18(2), 179-187 (2010).
67. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst. Rev. 2, CD006145 (2008).
68. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med. 358(22), 2332-2343 (2008). (Pubitemid 351749157)
69. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(6), 549-558 (2009).
70. Gan TJ, Gu J, Singla N et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth. Analg. 112(4), 804-812 (2011).
71. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303), 16-21 (2001). (Pubitemid 32681999)
72. Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr. Blood Cancer 56(2), 234-238 (2011).
73. Pearl ML, Fischer M, McCauley DL, Valea FA, Chalas E. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs. 22(4), 307-311 (1999). (Pubitemid 29368127)
74. Chi DS, Phaeton R, Miner TJ et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 14(8), 835-839 (2009).
75. Ryan M, Stainton MC, Jaconelli C, Watts S, MacKenzie P, Mansberg T. The experience of lower limb lymphedema for women after treatment for gynecologic cancer. Oncol. Nurs. Forum 30(3), 417-423 (2003).
76. Ryan M, Stainton MC, Slaytor EK, Jaconelli C, Watts S, Mackenzie P. Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust. NZJ Obstet. Gynaecol. 43(2), 148-151 (2003). (Pubitemid 36626120)
77. Gould N, Kamelle S, Tillmanns T et al. Predictors of complications after inguinal lymphadenectomy. Gynecol. Oncol. 82(2), 329-332 (2001). (Pubitemid 32730612)
78. Beesley V, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 109(12), 2607-2614 (2007). (Pubitemid 46906482)
79. Carlson JW, Kauderer J, Walker JL et al. A randomized Phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol. Oncol. 110(1), 76-82 (2008).
80. Kanakura Y, Niwa K, Kometani K et al. Effectiveness of acupuncture and moxibustion treatment for lymphedema following intrapelvic lymph node dissection: a preliminary report. Am. J. Chin. Med. 30(1), 37-43 (2002). (Pubitemid 41758919)
81. Schmitz KH, Ahmed RL, Troxel A et al. Weight lifting in women with breast-cancerrelated lymphedema. N. Engl. J. Med. 361(7), 664-673 (2009).
82. Schmitz KH, Ahmed RL, Troxel AB et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 304(24), 2699-2705 (2010).
83. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br. J. Surg. 83(1), 6-14 (1996). (Pubitemid 26018797)
84. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer 42(5), 589-597 (2006). (Pubitemid 43343680)
85. Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 71(6), 2027-2030 (1993). (Pubitemid 23068552)
86. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J. Pain Symptom Manage. 16(2), 96-101 (1998). (Pubitemid 28400159)
87. Faught W, Kirkpatrick JR, Krepart GV, Heywood MS, Lotocki RJ. Peritoneovenous shunt for palliation of gynecologic malignant ascites. J. Am. Coll. Surg. 180(4), 472-474 (1995).
88. Khabele D, Runowicz CD, Fields AL, Anderson PS, Goldberg GL. Evaluation of low-dose intraperitoneal interferon-a for palliation of ascites in patients with non-ovarian gynecologic malignancies. Gynecol. Oncol. 89(3), 420-423 (2003). (Pubitemid 36687786)
89. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12), 1242-1251 (2009).
90. Valente SM, Saunders JM, Cohen MZ. Evaluating depression among patients with cancer. Cancer Pract. 2(1), 65-71 (1994).
91. Chochinov HM, Wilson KG, Enns M, Lander S. 'Are you depressed?' Screening for depression in the terminally ill. Am. J. Psychiatry 154(5), 674-676 (1997). (Pubitemid 27198318)
92. Fisch M. Treatment of depression in cancer. J. Natl Cancer Inst. Monogr. 32, 105-111 (2004).
93. Ell K, Sanchez K, Vourlekis B et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J. Clin. Oncol. 23(13), 3052-3060 (2005). (Pubitemid 46224127)
94. Shalev AY, Schreiber S, Galai T, Melmed RN. Post-traumatic stress disorder following medical events. Br. J. Clin. Psychol. 32(Pt 2), 247-253 (1993). (Pubitemid 23177350)
95. Berard RM. Depression and anxiety in oncology: the psychiatrist's perspective. J. Clin. Psychiatry 62(Suppl. 8), 58-61; discussion 62-53 (2001).
96. Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L. Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur. J. Cancer 30A(1), 37-40 (1994). (Pubitemid 24058086)
97. Cella DF, Jacobsen PB, Orav EJ, Holland JC, Silberfarb PM, Rafla S. A brief POMS measure of distress for cancer patients. J. Chronic Dis. 40(10), 939-942 (1987). (Pubitemid 17132357)
98. Powell CB, Kneier A, Chen LM, Rubin M, Kronewetter C, Levine E. A randomized study of the effectiveness of a brief psychosocial intervention for women attending a gynecologic cancer clinic. Gynecol. Oncol. 111(1), 137-143 (2008).
99. Leon-Pizarro C, Gich I, Barthe E et al. A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psychooncology 16(11), 971-979 (2007). (Pubitemid 350081657)
100. Cain EN, Kohorn EI, Quinlan DM, Latimer K, Schwartz PE. Psychosocial benefits of a cancer support group. Cancer 57(1), 183-189 (1986). (Pubitemid 16212256)
101. Hersch J, Juraskova I, Price M, Mullan B. Psychosocial interventions and quality of life in gynaecological cancer patients: a systematic review. Psychooncology 18(8), 795-810 (2009).
102. Wilmoth MC, Botchway P. Psychosexual implications of breast and gynecologic cancer. Cancer Invest. 17(8), 631-636 (1999).
103. Aerts L, Enzlin P, Verhaeghe J, Vergote I, Amant F. Sexual and psychological functioning in women after pelvic surgery for gynaecological cancer. Eur. J. Gynaecol. Oncol. 30(6), 652-656 (2009).
104. Andersen BL, Woods XA, Copeland LJ. Sexual self-schema and sexual morbidity among gynecologic cancer survivors. J. Consult. Clin. Psychol. 65(2), 221-229 (1997). (Pubitemid 27147440)
105. Frumovitz M, Sun CC, Schover LR et al. Quality of life and sexual functioning in cervical cancer survivors. J. Clin. Oncol. 23(30), 7428-7436 (2005). (Pubitemid 46291804)
106. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J. Clin. Oncol. 22(5), 881-889 (2004). (Pubitemid 41103600)
107. Green MS, Naumann RW, Elliot M, Hall JB, Higgins RV, Grigsby JH. Sexual dysfunction following vulvectomy. Gynecol. Oncol. 77(1), 73-77 (2000). (Pubitemid 30217307)
108. Juraskova I, Butow P, Robertson R, Sharpe L, McLeod C, Hacker N. Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. Psychooncology 12(3), 267-279 (2003). (Pubitemid 36456870)
109. Carter J, Rowland K, Chi D et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol. Oncol. 97(1), 90-95 (2005). (Pubitemid 40403680)
110. Carter J, Chi DS, Brown CL et al. Cancer-related infertility in survivorship. Int. J. Gynecol. Cancer 20(1), 2-8 (2010).
111. Carter J, Raviv L, Applegarth L et al. A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistance. J. Cancer Surviv. 4(3), 236-246 (2010).
112. Brotto LA, Heiman JR, Goff B et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch. Sex. Behav. 37(2), 317-329 (2008). (Pubitemid 351423078)
113. Amsterdam A, Krychman ML. Sexual dysfunction in patients with gynecologic neoplasms: a retrospective pilot study. J. Sex Med. 3(4), 646-649 (2006).
114. Morrison RS, Penrod JD, Cassel JB et al. Cost savings associated with US hospital palliative care consultation programs. Arch. Intern. Med. 168(16), 1783-1790 (2008).
115. Goldsmith B, Dietrich J, Du Q, Morrison RS. Variability in access to hospital palliative care in the United States. J. Palliat. Med. 11(8), 1094-1102 (2008).
116. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363(8), 733-742 (2010).